Sign inJoin waitlistJoin the waitlist

IT

Irene Tsung

Physician · University of Michigan Health-Ann Arbor

Credentials: · · · ·

History

University of Michigan Health-Ann Arbor
2019–Present

Hematology and Medical Oncology
University of Michigan
2019–2022
Internal Medicine
University of Michigan
2016–2019
Indiana University School of Medicine
2012–2016

Research

Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy
Alimentary Pharmacology & Therapeutics · 2019 · First of 7 authors · 77 citations
A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma
The Oncologist · 2021 · First of 3 authors · 63 citations
Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis
Frontiers in Oncology · 2022 · 22 citations

Charles Nguyen
9 papers · 4 as a fellow
ZR
Zachary Reichert
7 papers
AA
Ajjai Alva
5 papers
Robert Fontana
5 papers
Ali Khaki
4 papers
Amanda Nizam
4 papers · 4 as a fellow
Cindy Jiang
4 papers · 4 as a fellow
Deepak Kilari
4 papers
Dimitra Bakaloudi
4 papers · 4 as a resident
HE
Hamid Emamekhoo
4 papers
Joaquim Bellmunt
4 papers
Matthew Campbell
4 papers

Clinical trials

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
Principal investigator · Recruiting · Phase 2
University of Michigan Rogel Cancer Center
2025–2028
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2035
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030